Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The asthma death problem revisited

R W Fuller1

  • 1Glaxo Wellcome plc, Uxbridge, UK.

British Journal of Clinical Pharmacology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Asthma deaths are a serious global concern, with epidemics noted historically. While some inhaled medications are suspected, other factors beyond therapy likely contribute to asthma mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistence of long-lasting serotonin depletion by p-chloroamphetamine in rat brain after 6-hydroxydopamine lesioning of dopamine neurons.

Biochemical pharmacology·1995
Same author

Assessing equivalence of inhaled drugs.

Respiratory medicine·1995
Same author

Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement--patterns of failure.

Radiology·1995
Same author

The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis.

Clinical otolaryngology and allied sciences·1995
Same author

Systemic effects of glucocorticoids--a response.

British journal of clinical pharmacology·1995
Same author

Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?

Chest·1995
Same journal

Anticholinergic and central nervous system-active drug burdens and their associations with adverse in-hospital outcomes among older inpatients.

British journal of clinical pharmacology·2026
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
See all related articles

Area of Science:

  • Pulmonary Medicine
  • Epidemiology

Background:

  • Asthma is a dangerous disease with global mortality, including historical epidemics.
  • Inhaled beta-adrenoceptor agonists, like fenoterol, have been investigated for their role in asthma epidemics.
  • Asthma deaths are not uniform, with distinct types related to disease severity and sudden anaphylactic events.

Purpose of the Study:

  • To analyze the multifaceted nature of asthma deaths.
  • To investigate factors contributing to asthma epidemics and background mortality.
  • To shift focus towards under-explored causes of asthma mortality.

Main Methods:

  • Review of historical and contemporary data on asthma mortality.
  • Analysis of epidemiological trends in asthma deaths.
  • Examination of potential contributing factors beyond therapeutic interventions.

Related Experiment Videos

Main Results:

  • Evidence suggests fenoterol may be implicated in some asthma epidemics, but data on other beta-adrenoceptor agonists is limited.
  • Asthma deaths can be categorized into those linked to chronic severe disease and sudden anaphylactic deaths.
  • Therapy alone cannot fully explain all observed asthma epidemics or background mortality rates.

Conclusions:

  • Further research into asthma deaths must consider factors beyond inhaled beta-adrenoceptor agonists.
  • Understanding the different mechanisms of asthma mortality is crucial for effective prevention.
  • Future studies should explore a broader range of contributing factors to reduce asthma-related deaths.